23andMe Overview
- Founded
-
2006
- Status
-
Public
- Employees
-
796
- Stock Symbol
-
ME
- Investments
-
4
- Share Price
-
$2.69
- (As of Friday Closing)
23andMe General Information
Description
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Contact Information
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Information Services (B2C)
Other Devices and Supplies
Biotechnology
Stock Exchange
NAS
Primary Office
- 223 North Mathilda Avenue
- Sunnyvale, CA 94086
- United States
+1 (800) 000-0000
23andMe Timeline
23andMe Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.69 | $2.75 | $2.02 - $6.31 | $1.23B | 455M | 2.64M | -$0.72 |
23andMe Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 896,092 | 1,214,005 | ||
| Revenue | 297,622 | 271,893 | 243,920 | 305,463 |
| EBITDA | (285,854) | (195,099) | (163,628) | (233,818) |
| Net Income | (314,537) | (217,490) | (183,619) | (250,863) |
| Total Assets | 1,040,732 | 1,152,068 | 452,098 | |
| Total Debt | 81,881 | 86,308 | 93,722 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
23andMe Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
23andMe Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
23andMe Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer persona
Laboratory Services (Healthcare)
Sunnyvale, CA
796
As of 2022
00.000
000000000
00.000
000000
elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000 00000000
Foster City, CA
000
As of 0000
00000
0000000 0000
00000
00000
tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000000000000
Aliso Viejo, CA
000
As of 0000
00
0000-00-00
000000&0
Add Comparison
23andMe Competitors (15)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MedGenome | Private Equity-Backed | Foster City, CA | 000 | 00000 | 0000000 0000 | 00000 |
| 00000 00000000 | Corporate Backed or Acquired | Aliso Viejo, CA | 000 | 000000&0 | ||
| 000000 000000 | Venture Capital-Backed | South Plainfield, NJ | 00 | 000000000 - | ||
| 00000 000000000 | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 0000000 0000 | |
| 000000000 00000000 | Formerly VC-backed | Espoo, Finland | 000 | 000.00 | 000000&0 | 000.00 |
23andMe Patents
23andMe Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220115139-A1 | Formatting and storage of genetic markers | Pending | 09-Oct-2020 | 000000000 | 0 |
| US-20220051751-A1 | Ancestry composition determination | Pending | 13-Aug-2020 | 000000000 | |
| CA-3178417-A1 | Anti-cd200r1 antibodies and methods of use thereof | Pending | 29-May-2020 | ||
| AU-2021281417-A1 | Anti-cd200r1 antibodies and methods of use thereof | Pending | 29-May-2020 | 00000000000 | |
| US-20210371521-A1 | Anti-cd200r1 antibodies and methods of use thereof | Pending | 29-May-2020 | C07K16/2803 | 0 |
23andMe Executive Team (44)
23andMe Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anne Wojcicki | 23andMe | Chief Executive Officer & Chairman | 000 0000 |
| Evan Lovell | VG Acquisition | Board Member | 000 0000 |
| Neal Mohan | Self | Board Member | 000 0000 |
| Patrick Chung JD | Xfund | Board Member | 000 0000 |
| Peter Taylor | Self | Board Member | 000 0000 |
23andMe Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
23andMe Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
23andMe Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 0000 | 01-Nov-2021 | 0000000000 | 00000 | Other Healthcare Services | 0000 0000 |
| 000000 (00000 | 07-Apr-2021 | 0000 00000 | 00.00 | Laboratory Services (Healthcare) | |
| 000000 00 000 | 20-Jul-2015 | 00000 0000 | 0000 | Other Healthcare Services | 0000 0000 |
| CureTogether | 10-Jul-2012 | Merger/Acquisition | Decision/Risk Analysis | 0000 0000 |
23andMe Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000000 000000 | Other Healthcare Services | San Francisco, CA | 0000 |
23andMe ESG
Risk Overview
Risk Rating
Updated October, 13, 2022
25.61 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 465
Rank
00.00
Percentile
23andMe Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00 000000 | 20-Jul-2015 | 00000 00000 00 | 0000 | Completed |
|